Biotechnology

Eledon Pharmaceuticals

Eledon Pharmaceuticals released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1719 (forecast USD -0.21)

Eledon Pharmaceuticals Inc. Short Interest Rises to 12.7%

Eledon Pharmaceuticals released FY2025 earnings on March 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5574 (forecast USD -0.6733)

Eledon Pharmaceuticals released FY2025 Q4 earnings on March 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1087 (forecast USD -0.2)

Eledon Pharmaceuticals released FY2025 Q3 earnings on November 14, 2025 (EST), with actual revenue USD 0 and EPS USD -0.2259 (forecasted EPS USD -0.2457)

Eledon Pharmaceuticals released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.4554

Eledon Pharmaceuticals Reports Positive Results for Tegetprubart's Phase 2 Trial

Eledon Pharmaceuticals released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -0.2295

Eledon Pharmaceuticals released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1453 (forecast USD -0.23)

Eledon to Present Tegoprubart's Phase 1b Clinical Trial Update at San Francisco Transplant Conference

Eledon Pharmaceuticals Hosts R&D Day Event

Velan Capital Invests in Eledon Pharmaceuticals

Sphera Increases Holdings in Eledon

Eledon Pharmaceuticals released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0338 (forecast USD -0.3033)

Eledon Pharmaceuticals Q1 2025 Financial Report and Future R&D Plans

Eledon Pharmaceuticals' quarterly earnings fall short of expectations, analysts remain optimistic

Eledon Pharmaceuticals released FY2024 Q4 earnings on March 20 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6789 (forecast USD -0.3266)

Eledon Pharmaceuticals released FY2024 earnings on March 20 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.7453 USD (forecast -0.7133 USD)

Eledon Pharmaceuticals released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2824 (forecast USD -0.296)

Eledon Pharmaceuticals released FY2024 9 Months Earnings on November 12 (EST) with actual revenue of USD 0 and EPS of USD -2.1656

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

ELDN

Eledon will be showcasing updated long-term results from the Phase 2 BESTOW trial of Tegoprubart at the upcoming ATC conference. The trial focuses on leveraging Tegoprubart to prevent rejection in kidney transplant patients. The data to be presented includes significant improvements in rejection rates, with a notable reduction of 30% compared to current standard treatments. This landmark research highlights the potential of Tegoprubart as a promising option in the field of transplant medicine.

Unusual Whales

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Earnings Watch

Eledon Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Eledon Pharmaceuticals (NASDAQ:ELDN) is set to announce its Q1 2026 earnings on May 13, with analysts predicting a loss of $0.22 per share. The company previously reported a loss of $0.10 per share in Q4 2025, exceeding estimates. ELDN stock opened at $3.78, with a market cap of $286.72 million. Analysts have mixed ratings, with a consensus rating of "Hold" and a price target of $9.67. Institutional investors hold 56.77% of the stock, and the company focuses on therapies for smooth muscle dysfunction.

Market Beat

BNP Paribas

Virtu Finc

Eledon Pharmaceuticals (ELDN) Expected to Announce Earnings on Wednesday

NCEL

NewcelX Ltd. (Nasdaq: NCEL) has updated its corporate presentation to emphasize its strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and the advancement of its flagship Type 1 Diabetes program, NCEL-101. This collaboration integrates NewcelX’s stem-cell-derived islet replacement platform with Eledon’s immune-modulation therapy, aiming to enhance graft survival and potentially provide a functional cure for Type 1 Diabetes. The updated presentation will be showcased at the Swiss Biotech Conference, highlighting NewcelX's development strategy and vision for the program.

StockTitan

NewcelX

NEWCELX LTD C/WTS 02/02/2026(TO PUR COM)

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference | NCEL Stock News

Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines | ELDN Stock News

Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines | ELDN Stock News

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) experienced a 30.3% increase in short interest in March, totaling 8,417,915 shares. This represents approximately 12.7% of the company's stock being short sold, with a short-interest ratio of 6.5 days based on an average daily trading volume of 1,292,590 shares. The stock traded down to $2.83, with a market cap of $214.66 million. Analysts have a consensus rating of "Hold" for ELDN, with an average price target of $9.67. Institutional investors hold 56.77% of the stock, reflecting significant interest in the company.

Eledon Pharmaceuticals(ELDN.US)

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Eledon Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Eledon Pharmaceuticals (ELDN) Expected to Announce Earnings on Wednesday

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference | NCEL Stock News

Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines | ELDN Stock News

Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3%